Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 15, Issue 5, 2008, Pages 545-548

  Morise, Zenichi ^a   Sugioka, Atsushi ^a   Hoshimoto, Sojun ^a   Kato, Takazumi ^a   Tanahashi, Yoshinao ^a   Ikeda, Masahiro ^a   Kagawa, Tadashi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Intrahepatic cholangiocarcinoma; Surgery

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; UFT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY METASTASIS; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; REOPERATION; SURVIVAL TIME; SYMPTOM;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; SURVIVORS;

EID: 53549093881     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-007-1270-1     Document Type: Article

References (10)

1. Ishak KG, Goodman ZD, Stocker JT. Tumors of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology, 3rd series, fascicle 31. Washington, DC: Armed Forces Institute of Pathology; 2001.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.
3. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42.
4. Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:432-440.
5. Kaneoka Y, Yamaguchi A, Isogai M. Hepatopancreatoduodenectomy: Its suitability for bile duct cancer versus gallbladder cancer. J Hepatobiliary Pancreat Surg. 2007;14:142-148.
6. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520.
7. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-2048.
8. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005;16:iI93-ii96.
9. Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S. Gemcitabine in combination with EGF-receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: A case report. BMC Cancer 2006;6:190.
10. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676.